^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers

Published date:
09/19/2020
Excerpt:
In pts with elevated immune gene expression signatures, lower TGFb expression was associated with greater OS benefit with avelumab.